Dendritic cell immunotherapy for glioblastoma |
| |
| Affiliation: | 1. Department of Neurosurgery, King’s College Hospital,Denmark Hill London, SE5 9RS, UK &2. Keyoumars Ashkan Department of Neurosurgery, King’s College Hospital,Denmark Hill London, SE5 9RS, UKk.ashkan@nhs.net |
| |
| Abstract: | Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed. |
| |
| Keywords: | dendritic cell glioblastoma multiforme immunotherapy overall survival side-effect |
|
|
